BASELINE CHARACTERISTICS AND TREATMENT EFFICACY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2a AND RIBAVIRIN IN 253 HCV GENOTYPE 1 NONRESPONDER PATIENTS IN A REAL-WORLD SETTING

被引：1

作者：

Hofmann, W. P. ^{[1
]}

Mauss, S. ^{[2
]}

Baumgarten, A. ^{[3
]}

Boeker, K. H. W. ^{[4
]}

Link, R. ^{[5
]}

Naumann, U. ^{[6
]}

Geyer, P. R. ^{[7
]}

Schuchmann, M. ^{[8
]}

Stoehr, A. ^{[9
]}

Loehr, H. ^{[10
]}

Schober, A. ^{[11
]}

Moog, G. ^{[12
]}

Holm, S. ^{[13
]}

Heyne, R. ^{[14
]}

Eisenbach, C. ^{[15
]}

Lutz, T. ^{[16
]}

Alshuth, U. ^{[17
]}

Hueppe, D. ^{[18
]}

机构：

[1] Polikum Inst, Berlin, Germany

[2] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany

[3] Mib Dienstleistung GmbH, Berlin, Germany

[4] Ctr Hepatol, Hannover, Germany

[5] MZV Offenburg, Offenburg, Germany

[6] Praxiszentrum Kaiserdamm, Ctr Addict Med Hepatol & HIV, Berlin, Germany

[7] Ctr Gastroenterol, Fulda, Germany

[8] Johannes Gutenberg Univ Mainz, Dept Med Gastroenterol & Hepatol 1, D-55122 Mainz, Germany

[9] Ifi Inst Interdisciplinary Med, Hamburg, Germany

[10] Ctr Gastroenterol, Wiesbaden, Germany

[11] Ctr Gastroenterol, Gottingen, Germany

[12] Ctr Gastroenterol, Kassel, Germany

[13] Private Practice Dres Kuhlmann Holm Heiken, Hannover, Germany

[14] Liver & Study Ctr Checkpoint, Berlin, Germany

[15] Heidelberg Univ, Dept Gastroenterol, Heidelberg, Germany

[16] Infektiologikum, Frankfurt, Germany

[17] Roche Pharma AG, Virol, Grenzach Wyhlen, Germany

[18] Ctr Gastroenterol, Herne, Germany

来源：

JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期

关键词：

D O I：

10.1016/S0168-8278(14)61310-6

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P1150

引用

页码：S466 / S466

页数：1

共 50 条

[1] Telaprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with genotype 1 HCV and mild to moderate liver disease
Zeuzem, Stefan
DeMasi, Ralph
Foster, Graham R.
Buti, Maria
Laeuffer, Joerg M.
Luo, Donghan
Witek, James
Rizzetto, Mario
[J]. HEPATOLOGY, 2013, 58 : 1129A - 1129A
[2] Twice Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Safety/Efficacy of the REFRESH Study
Brown, R.
Russo, M.
Levitsky, J.
Brown, K.
Fontana, R.
Vargas, H.
Yoshida, E.
Bsharat, M.
Rubin, R.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 145 - 145
[3] Peginterferon alfa-2a/ribavirin treatment in patients with chronic HCV genotype 1: Efficacy is improved in patients with early stages of fibrosis
Shiffman, ML
Fried, MW
Marcellin, P
Govindarajan, S
Lopez-Talavera, JC
Pockros, PJ
[J]. GASTROENTEROLOGY, 2005, 128 (04) : A722 - A722
[4] TELAPREVIR COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN IN HCV/HIV COINFECTED PATIENTS: 24-WEEK TREATMENT INTERIM ANALYSIS
Sherman, Kenneth E.
Rockstroh, Juergen K.
Dieterich, Douglas T.
Soriano, Vincent
Girard, Pierre-Marie
McCallister, Scott
Adda, Nathalie
Adiwijaya, Bambang S.
Mahnke, Lisa
Sulkowski, Mark S.
[J]. HEPATOLOGY, 2011, 54 : 1431A - 1431A
[5] REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY
Mauss, S.
Boeker, K. H. W.
Eisenbach, C.
Moeller, B.
Moog, G.
Lutz, T.
Naumann, U.
Christensen, S.
Jung, M. -C.
Teuber, G.
Doss, M. Frank
Schuchmann, M.
Schott, E.
Alshuth, U.
Hueppe, D.
[J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S357 - S358
[6] A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
Flisiak, Robert
Shiffman, Mitchell
Arenas, Juan
Cheinquer, Hugo
Nikitin, Igor
Dong, Yuping
Rena, Khurram
Srinivasan, Subasree
[J]. PLOS ONE, 2016, 11 (10):
[7] RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTS
Benhamou, Y.
Moussalli, J.
Ratziu, V.
Lebray, P.
Gysen, V.
de Backer, K.
Ghys, A.
van Heeswijk, R.
Vangeneugden, I.
Picchio, G.
Beumont-Mauviel, M.
[J]. JOURNAL OF HEPATOLOGY, 2009, 50 : S6 - S6
[8] Twice Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Pharmacokinetics of the REFRESH Study.
Vargas, H.
Dai, Y.
Brown, K.
Russo, M.
Yoshida, E.
Fontana, R.
Levitsky, J.
Rubin, R.
Garg, V.
Brown, R.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 347 - 347
[9] Peginterferon Alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1
Jeffers, LJ
Cassidy, W
Howell, CD
Hu, S
Reddy, KR
[J]. HEPATOLOGY, 2004, 39 (06) : 1702 - 1708
[10] Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1
Pijak, MR
Gazdik, F
Hrusovsky, S
[J]. HEPATOLOGY, 2004, 40 (03) : 760 - 761

← 1 2 3 4 5 →